8024 GFP_Kras_G12C_2A_puro
(Plasmid
#64373)
-
PurposeThis a retroviral expression plasmid expressing GFP tagged G12C mutant Kras 2A oncogene along with puro resistance gene
-
Depositing Lab
-
Sequence Information
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 64373 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backbone7432 Bicistronic_GFP_ires_puro
-
Backbone manufacturerTheodora Agalioti
- Backbone size w/o insert (bp) 7432
- Total vector size (bp) 8047
-
Modifications to backboneAgeI, HpaI
-
Vector typeRetroviral
-
Selectable markersPuromycin
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)XL1 Blue
-
Copy numberHigh Copy
Gene/Insert
-
Gene/Insert namemouse Kras2A
-
Alt nameKras
-
SpeciesM. musculus (mouse)
-
Insert Size (bp)1356
-
Mutationchanged glycine 12 to cysteine
-
Entrez GeneKras (a.k.a. K-Ras, K-Ras 2, K-ras, Ki-ras, Kras-2, Kras2, c-K-ras, c-Ki-ras, p21B, ras)
-
Tag
/ Fusion Protein
- GFP (N terminal on insert)
Cloning Information
- Cloning method Restriction Enzyme
- 5′ cloning site AgeI (not destroyed)
- 3′ cloning site SmaI (destroyed during cloning)
- 5′ sequencing primer ccctcactccttctctagg (Common Sequencing Primers)
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
Depositor Comments
This plasmid was constructed by Theodora Agalioti in G. Stathopoulos Lab in Patras, Greece.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
8024 GFP_Kras_G12C_2A_puro was a gift from Georgios Stathopoulos (Addgene plasmid # 64373 ; http://n2t.net/addgene:64373 ; RRID:Addgene_64373) -
For your References section:
Mutant KRAS promotes malignant pleural effusion formation. Agalioti T, Giannou AD, Krontira AC, Kanellakis NI, Kati D, Vreka M, Pepe M, Spella M, Lilis I, Zazara DE, Nikolouli E, Spiropoulou N, Papadakis A, Papadia K, Voulgaridis A, Harokopos V, Stamou P, Meiners S, Eickelberg O, Snyder LA, Antimisiaris SG, Kardamakis D, Psallidas I, Marazioti A, Stathopoulos GT. Nat Commun. 2017 May 16;8:15205. doi: 10.1038/ncomms15205. 10.1038/ncomms15205 PubMed 28508873